Table 4.

Gene signature associated to clinical benefit of MAGE-A3 ASCI in phase II studies in melanoma and NSCLC patients [from Ascierto and colleagues (73)]

Phase II studies evaluating the MAGE-A3 ASCI
Phase II NSCLC (NCT 00290355)Phase II Melanoma (NCT 00086866)
GS−25% Relative improvement (DFI)OS of 16.2 months
GS+53% Relative improvement (DFI)OS of 28.0 months

Abbreviations: DFI, disease-free interval; GS−, population in which the gene signature was not found; GS+, population for which a specific gene signature has been defined.